Article first published in the Sustainable Healthcare report, distributed in The Guardian on 24th June 2021
The pandemic has put pharmaceutical companies into the spotlight, however their value is not just in supplying treatments but partnering with the system to support progress.
Before working at Bristol Myers Squibb, I’d assumed that the pharmaceutical industry wholly focussed on providing new treatments to patients. Of course, developing new treatments for patients that help them to manage their disease, stay well and live life to the full, in itself is an incredibly complex task. But it’s appreciating the network of activity that goes on all around this core purpose that has been a huge learning experience for me. An experience that I believe the wider public and media are understanding more, particularly in the wake of the pandemic.